Tempest Therapeutics (TPST) Cash from Financing Activities (2012 - 2025)

Tempest Therapeutics has reported Cash from Financing Activities for 14 years, with the latest figure at $3.8 million in Q4 2025.

• Quarterly Cash from Financing Activities fell 79.02% year-over-year to $3.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.3 million (down 82.62% YoY) and the FY2025 annual result came in at $4.3 million, down 82.62% from the prior year.
• Cash from Financing Activities grew to $3.8 million in Q4 2025 per TPST's latest filing, from $13000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $41.0 million in Q2 2021 and troughed at -$4.7 million in Q4 2022.
• A 5-year average of $6.7 million and a median of $1.3 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities soared 28690.91% in 2021, then plunged 52411.11% in 2022.
• Over 5 years, Cash from Financing Activities stood at -$9000.0 in 2021, then slumped by 52411.11% to -$4.7 million in 2022, then surged by 826.81% to $34.3 million in 2023, then tumbled by 47.74% to $18.0 million in 2024, then sank by 79.02% to $3.8 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $3.8 million, $13000.0, and $1.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.